Apr 03,2020

Pear Therapeutics Presents Data at ASAM Virtual 2020 Program Demonstrating High Satisfaction and Engagement for reSET and reSET-O

Pear Therapeutics, Inc. presented results today from an open-label study that evaluated participant engagement and satisfaction with reSET® and reSET-O®, prescription digital therapeutics (PDTs) that deliver evidence-based disease treatment through cognitive behavioral therapy, fluency training and contingency management for substance use disorder (SUD) and opioid use disorder (OUD) via mobile device. This open-label study (Hassman Research Institute) enrolled 34 outpatient participants with SUD (n=17) and OUD (n=17). Participants received reSET (90 days) or reSET-O (84 days) with biweekly therapist appointments and urine drug screens (UDS). Nearly all participants were motivated/very motivated to use their PDT at baseline. Continued engagement was observed throughout the 12-week study, with the majority of participants (59% reSET; 71% reSET-O) still using their PDT at week 12.

CLINICAL STUDY

#mobile app

#pdt

View Analyst & Ambassador Comments
Go to original news
Apr 07,2020

Propeller data shows 14.5% med adherence lift since COVID-19 outbreak began

With hospitals overburdened with COVID-19 cases, it’s essential that patients with asthma and COPD stay home if possible, both to avoid infection and keep emergency rooms free for people experiencing coronavirus symptoms. The data from 7,578 Propeller users shows that patients are taking their preventative health more seriously than ever with the help of our digital health tool. Since the COVID-19 outbreak began to ramp up in January, patients have become 14.5% more adherent to their controller medication regimen, with most of that improvement noted in the last 4 weeks.

CLINICAL STUDY

#connected device

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 01,2020

Omada for Diabetes Program Achieves Key Clinical Outcomes

New data from an initial cohort of participants in the Omada for Diabetes Program demonstrates that participants achieved clinically-meaningful reductions in hemoglobin A1C levels as measured by blood test. Participants who began the program with a baseline A1C level at or above 7 percent reduced their A1C by 1.1 points, on average. Those with a baseline A1C below 7 percent maintained their A1C at goal, as measured by treatment guidelines published by the American Diabetes Association. Overall, 85 percent of participants in the group achieved their A1C goals while in the Omada Program. Blood value reductions were recorded among participants with both a baseline and follow-up A1C value from either participant-reported lab data, or an at-home A1C test kit.

CLINICAL STUDY

#coaching

#connected device

View Analyst & Ambassador Comments
Go to original news
May 12,2020

Digital Therapeutic Sleepio™ Yields 28% Lower Healthcare Costs

Big Health, the global leader in digital therapeutics dedicated to helping millions back to good mental health, today announced key findings from a health economic evaluation of Sleepio™, a digital sleep improvement program. The study was conducted at a self-insured Fortune 500 company, in collaboration with IBM Watson Health, and Dr. Laurence Baker, a health economic consultant. Dr. Baker also holds an appointment as a Professor of Health Research and Policy at Stanford University. The study compared two groups of employees—a group of Sleepio users and a matched control group—and compared their respective healthcare costs over an 18-month follow-up period. The results demonstrated 28% lower total healthcare costs in the cohort of Sleepio users, as compared to the matched control group.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
May 14,2020

ML Models Trained With Patient-Reported Data Can Predict Onset And Presence Of Immune-Related Adverse Events

The cooperative research between Kaiku Health and Oulu University Hospital aimed to investigate whether patient-reported symptom data (Patient-Reported Outcomes) could be used as an input for machine learning-based prediction models for early detection of immune-related adverse events (irAEs). The research was published at ASCO Annual Meeting 2020 Online Publication on the 13th of May, 2020. The results suggest that machine learning-based prediction models, using patient-reported symptom data as input for the models, can predict the presence and onset of irAEs with high accuracy.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Jun 15,2020

One Drop Announces Long-term Outcomes Forecasts for Diabetes-related Biomarkers and Overnight Hypoglycemia Predictions for CGM Users

One Drop, a leader in digital therapeutics solutions for people living with diabetes and other chronic conditions, presented long-term A1C, blood pressure, and weight outcomes forecasts for individuals, along with overnight hypoglycemia predictions for CGM users at the 80th Annual American Diabetes Association Virtual Scientific Sessions. New predictions lay the foundation for One Drop’s highly personalized and adaptive data-driven health products.

CLINICAL STUDY

#software

View Analyst & Ambassador Comments
Go to original news
Jun 15,2020

DarioHealth Presents New Studies Demonstrating Sustained Improvements in Blood Glucose and Blood Pressure Control

DarioHealth Corp. (Nasdaq: DRIO), a leading global digital therapeutics (DTx) company, presented the results of two new studies at the American Diabetes Association's (ADA) 80th Scientific Sessions that showed sustained improvements in blood glucose levels and blood pressure among users of its digital therapeutic platform for chronic diseases. In the first study, Dario conducted a twelve-month retrospective analysis of 9,200 non-insulin treated Type-2 diabetes (T2D) users of the Dario digital therapeutic platform for chronic disease. A subgroup of users who participated in hypertension management were also evaluated. Key results included the following: The average ratio of high blood glucose events (180-400 mg/dL) was reduced by 26% and sustained during the full year, and 71% of members using the hypertension therapeutic succeeded in reducing their systolic blood pressure by 8.1 mmHg and diastolic by 6.0 mmHg on average and 38% succeeded in reducing their blood pressure by one stage.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 22,2020

Digital health drives positive changes in behavior for people with respiratory conditions

Propeller Health presents the its latest findings on patient behavior from the users benefiting Propeller mobile app. In a study group of 3,511 adults with asthma and 1,159 adults with COPD who used Propeller to manage their condition, engagement with the Propeller mobile app was associated with significant increases in adherence to controller medications, which are crucial to keeping symptoms under control.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 09,2020

First Scientific Study Using Virtual Reality to Treat Chronic Pain at Home Finds AppliedVR Platform Feasible, Scalable and Effective

AppliedVR, a pioneer advancing the next generation of digital medicine, today announced results from the first randomized controlled trial (RCT), evaluating virtual-reality-based (VR) therapy for self-management of chronic pain at home. The study, which was published in JMIR-FR, found that a self-administered, skills-based VR treatment program was not only a feasible and scalable way to treat chronic pain, it also was effective at improving on multiple chronic pain outcomes. The study analyzed data from 74 people who suffer from chronic lower-back or fibromyalgia pain over a 21-day period and showed that participants using AppliedVR’s EaseVR program significantly reduced five key pain indicators - each of which met or exceeded the 30-percent threshold for clinically meaningful.

CLINICAL STUDY

#virtual reality

#connected device

View Analyst & Ambassador Comments
Go to original news
Jul 14,2020

Research finds that digital therapeutic app can ease symptoms of ‘chemo brain’ in breast cancer patients

In a clinical trial at the University of Antwerp, between 2016 and 2020, experts investigated whether the digital therapeutic app MyCognition is an effective approach to assess and improve cognitive decline, alongside standard care for the rehabilitation of breast cancer. The study found that using the digital therapeutic app MyCognition can ease perception of cognitive decline in breast cancer patients. Around 75% of breast cancer patients report experiencing cognitive decline known as ‘chemo brain’ during or after treatment, according to research. MyCognition is a UK-based company which researches, develops and creates digital therapeutics to measure and enhance cognitive fitness. Its apps have been approved by the NHS.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY